> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-206/
- Published: 2018-12-02T12:00:00.000Z
- Updated: 2026-09-15T00:48:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142946

[**Draft Guide on Blood Glucose Monitoring 510(k)s**](https://www.fdaweb.com/draft-guide-on-blood-glucose-monitoring-510-k-s/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use.” 11/30/2018

[**Draft Guide on OTC Blood Glucose Monitors**](https://www.fdaweb.com/draft-guide-on-otc-blood-glucose-monitors/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use.” 11/30/2018

[**Panel to Review Amgen Osteoporosis Therapy BLA**](https://www.fdaweb.com/panel-to-review-amgen-osteoporosis-therapy-bla/)  
*Federal Register* notice: FDA announces a 1/16 Bone, Reproductive and Urologic Drugs Advisory Committee meeting to discuss an Amgen BLA for osteoporosis therapy romosozumab injection. 11/30/2018

[**Joint Panels to Review Uloric Cardiovascular Safety**](https://www.fdaweb.com/joint-panels-to-review-uloric-cardiovascular-safety/)  
*Federal Register* notice: FDA announces a 1/11/2019 joint meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting to review Takeda drug Uloric’s cardiovascular safety. 11/29/2018

[**FDA Updates ANDA Product-specific Guides**](https://www.fdaweb.com/fda-updates-anda-product-specific-guides/)  
*Federal Register* notice: FDA issues 22 new and 41 revised ANDA product-specific guidances. 11/29/2018

[**Draft Guide on Dual 510(k) and CLIA Waiver**](https://www.fdaweb.com/draft-guide-on-dual-510-k-and-clia-waiver-2/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Recommendations for Dual 510(k) and Clinical Laboratory Improvement Amendments (CLIA) Waiver by Application Studies.” 11/29/2018

[**Panel to Review Sanofi Diabetes Drug**](https://www.fdaweb.com/panel-to-review-sanofi-diabetes-drug/)  
*Federal Register* notice: FDA announces a 1/17/2019 Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss a Sanofi-Aventis NDA for diabetes drug sotagliflozin. 11/29/2018

[**Draft Guide on CLIA Recommendations**](https://www.fdaweb.com/draft-guide-on-clia-recommendations-2/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Select Updates for Recommendations for Clinical Laboratory Improvement Amendments of 1988 Waiver Applications for Manufacturers of In Vitro Diagnostic Devices.” 11/29/2018